Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients
Objective:Published studies on male breast cancer (MBC) and BRCA mutations are scarce and usually include, a small number of patients. The clinicopathological characteristics of BRCA mutant and wild-type MBC patients were compared in more than forty patients in this study.Materials and Methods:A ret...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-10-01
|
| Series: | European Journal of Breast Health |
| Subjects: | |
| Online Access: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/comparison-of-clinical-pathological-and-prognostic/53091
|
| _version_ | 1797915869319266304 |
|---|---|
| author | İzzet Doğan Esra Aydın Hülya Yazıcı Pınar Saip |
| author_facet | İzzet Doğan Esra Aydın Hülya Yazıcı Pınar Saip |
| author_sort | İzzet Doğan |
| collection | DOAJ |
| description | Objective:Published studies on male breast cancer (MBC) and BRCA mutations are scarce and usually include, a small number of patients. The clinicopathological characteristics of BRCA mutant and wild-type MBC patients were compared in more than forty patients in this study.Materials and Methods:A retrospective review of MBC patients’ clinical and histopathological data was conducted. To compare the patients’ characteristics, chi-square test and Fisher's Exact test were utilized. Kaplan–Meier analysis was used to examine the survival analysis.Results:In total 43 cases were reviewed. The average duration of follow-up was 35.8 months. BRCA mutations were found in 11 (25.6%) of the patients. BRCA1 mutations were found in four patients (9.3%), BRCA2 mutations in six patients (14%), and BRCA1 and BRCA2 mutations in one patient (2.3%). The median age at diagnosis was 58 years old, and there was no statistically significant difference between groups (p = 0.7). Tumor location (p = 0.3), human epidermal growth factor receptor 2 overexpression (p = 0.5), estrogen receptor status (p = 0.05), progesterone receptor status (p = 0.6), tumor stage (p = 0.9), lymph node positivity (p = 0.5), tumor histology (p = 0.06), and recurrence status (p = 0.6) were similar between BRCA-wild type and -mutated patients. Overall survival averaged 115.6 months (range: 76.0–155.3), with no statistically significant differences between groups (p = 0.6).Conclusion:This study investigated clinical and pathological characteristics and prognoses of BRCA wild and mutant-type MBC and these were similar in all groups studied. |
| first_indexed | 2024-04-10T12:48:16Z |
| format | Article |
| id | doaj.art-493a4dc1f5d040a9b2c9db63d93ad580 |
| institution | Directory Open Access Journal |
| issn | 2587-0831 |
| language | English |
| last_indexed | 2024-04-10T12:48:16Z |
| publishDate | 2022-10-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | European Journal of Breast Health |
| spelling | doaj.art-493a4dc1f5d040a9b2c9db63d93ad5802023-02-15T16:13:56ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312022-10-0118432332810.4274/ejbh.galenos.2022.2022-5-213049054Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patientsİzzet Doğan0Esra Aydın1Hülya Yazıcı2Pınar Saip3 Department of Medical Oncology, İstanbul University Institute of Oncology, İstanbul, Turkey Department of Medical Oncology, İstanbul University Institute of Oncology, İstanbul, Turkey Department of Cancer Genetics, İstanbul University Institute of Oncology, İstanbul, Turkey Department of Medical Oncology, İstanbul University Institute of Oncology, İstanbul, Turkey Objective:Published studies on male breast cancer (MBC) and BRCA mutations are scarce and usually include, a small number of patients. The clinicopathological characteristics of BRCA mutant and wild-type MBC patients were compared in more than forty patients in this study.Materials and Methods:A retrospective review of MBC patients’ clinical and histopathological data was conducted. To compare the patients’ characteristics, chi-square test and Fisher's Exact test were utilized. Kaplan–Meier analysis was used to examine the survival analysis.Results:In total 43 cases were reviewed. The average duration of follow-up was 35.8 months. BRCA mutations were found in 11 (25.6%) of the patients. BRCA1 mutations were found in four patients (9.3%), BRCA2 mutations in six patients (14%), and BRCA1 and BRCA2 mutations in one patient (2.3%). The median age at diagnosis was 58 years old, and there was no statistically significant difference between groups (p = 0.7). Tumor location (p = 0.3), human epidermal growth factor receptor 2 overexpression (p = 0.5), estrogen receptor status (p = 0.05), progesterone receptor status (p = 0.6), tumor stage (p = 0.9), lymph node positivity (p = 0.5), tumor histology (p = 0.06), and recurrence status (p = 0.6) were similar between BRCA-wild type and -mutated patients. Overall survival averaged 115.6 months (range: 76.0–155.3), with no statistically significant differences between groups (p = 0.6).Conclusion:This study investigated clinical and pathological characteristics and prognoses of BRCA wild and mutant-type MBC and these were similar in all groups studied. http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/comparison-of-clinical-pathological-and-prognostic/53091 brca mutationsmale breast cancerpathology featuresprognosis |
| spellingShingle | İzzet Doğan Esra Aydın Hülya Yazıcı Pınar Saip Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients European Journal of Breast Health brca mutations male breast cancer pathology features prognosis |
| title | Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients |
| title_full | Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients |
| title_fullStr | Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients |
| title_full_unstemmed | Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients |
| title_short | Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients |
| title_sort | comparison of clinical pathological and prognostic features in brca mutant and wild type male breast cancer patients |
| topic | brca mutations male breast cancer pathology features prognosis |
| url |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/comparison-of-clinical-pathological-and-prognostic/53091
|
| work_keys_str_mv | AT izzetdogan comparisonofclinicalpathologicalandprognosticfeaturesinbrcamutantandwildtypemalebreastcancerpatients AT esraaydın comparisonofclinicalpathologicalandprognosticfeaturesinbrcamutantandwildtypemalebreastcancerpatients AT hulyayazıcı comparisonofclinicalpathologicalandprognosticfeaturesinbrcamutantandwildtypemalebreastcancerpatients AT pınarsaip comparisonofclinicalpathologicalandprognosticfeaturesinbrcamutantandwildtypemalebreastcancerpatients |